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Although anti-C1q autoantibodies have been described more than four decades ago a
constant stream of papers describing clinical associations or functional consequences
highlights that anti-C1q antibodies are still hot and happening. By far the largest set of
studies focus on anti-C1q antibodies is systemic lupus erythematosus (SLE). In SLE anti-
C1q antibodies associate with involvement of lupus nephritis in such a way that in the
absence of anti-C1q antibodies it is unlikely that a flare in nephritis will occur. Anti-C1q anti-
bodies occur in several autoimmune conditions but also in healthy individuals. Although
considerable progress has been made in the understanding of how anti-C1q antibodies
may contribute to tissue injury there is still a lot to learn about the processes involved
in the breaking of tolerance to this protein. There has been considerable improvement in
the assays employed to test for the presence of anti-C1q antibodies. Hopefully with these
new and standardized assays at hand larger clinical association studies will be conducted
with independent replication. Such large-scale studies will reveal the true value of clinical
testing for anti-C1q autoantibodies in several clinical conditions.
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INTRODUCTION
Of all the autoantibodies that target complement proteins, anti-
C1q autoantibodies have received most attention (Trouw et al.,
2001; Norsworthy and Davies, 2003). C1q, the initiation molecule
of the classical pathway of complement activation, has a unique
capacity to bind to the Fc tail of subclasses of IgG and IgM anti-
bodies (Daha et al., 2011). C1q does so only when at least two
IgG molecules are spatially oriented in such a way that they can
simultaneously interact with one C1q molecule as for example in
an immune-complex (Cooper, 1985). Alternatively, C1q can bind
to a single IgM molecule in a “staple” like configuration (Feinstein
et al., 1971). The binding of C1q to non-aggregated IgG mole-
cules or fluid-phase IgM is weak. The fact that C1q can bind IgG
in immune complexes can be considered as both a blessing and a
curse. The blessing lies in the fact that the identification of anti-
C1q antibodies was a consequence of studies on size fractionations
of immune complexes that could bind to C1q. In these studies it
was subsequently discovered that in systemic lupus erythemato-
sus (SLE) patients next to the high molecular weight fractions
also low-molecular weight fractions contained immunoglobulins
that could bind to C1q (Agnello et al., 1971) (Table 1). In the
following years these low-molecular weight fractions were fur-
ther identified as monomeric, non-complexed IgG molecules that
specifically interacted with the collagen-like tail of the C1q mol-
ecule (Uwatoko et al., 1984, 1987; Antes et al., 1988). The curse
lies in the fact that special care has to be taken to discriminate
between IgG in immune complexes binding to C1q and anti-C1q
autoantibodies binding to C1q (Kohro-Kawata et al., 2002). This
problem can be overcome by adding 1 M NaCl to the incubation
buffer in the assay. The low-avidity interactions between the C1q
globular head domains with the CH2 domains of IgG Fc tails is
completely disrupted in these conditions, whereas the high avid-
ity binding of anti-C1q autoantibodies to the collagen-like tail of
C1q is kept intact (Kohro-Kawata et al., 2002). It is currently not
known to what extend the high salt conditions may lead to an
underestimation of low-avidity anti-C1q autoantibodies.
ASSAYS TO DETECT ANTI-C1Q AUTOANTIBODIES
Over time several assays have been developed to detect anti-C1q
autoantibodies both in humans and in experimental animal mod-
els. The first assays employed a direct coating of intact C1q, which
necessitated the use of high salt conditions to discriminate between
immune-complex binding and anti-C1q autoantibody binding
(Kohro-Kawata et al., 2002). Already early in the history of anti-
C1q autoantibodies it was discovered that the majority of these
autoantibodies is directed against the collagen-like part of the
C1q molecule (Antes et al., 1988). From equilibrium studies and
from the observation that anti-C1q antibodies can be found in
the presence of freely circulating C1q it was argued that anti-C1q
antibodies may interact with epitopes that are not exposed in C1q
in fluid phase (Golan et al., 1982). Later these arguments were
supported by elegant studies using phage display technology gen-
erated Fab fragments that only interacted with solid-phase C1q
(Schaller et al., 2009). Next, assays have been developed that uti-
lized only the C1q collagen-like region, generated by enzymatic
digestions as antigen (Antes et al., 1988; Wener et al., 1989). This
eliminated the need to use high-ionic strength buffer. A recent
paper reports on the use of peptides derived from C1q that have
interesting properties to detect a major linear epitope in a high
percentage of the patients in the absence of high-ionic strength
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Table 1 | History of anti-C1q antibodies.
Year Milestone Reference
1971/88 Identification of C1q as the target of autoantibodies Agnello et al. (1971), Antes et al. (1988)
1982 C1q in solid-phase exposes neo-epitopes Golan et al. (1982)
1984 Identification of the collagen-like stalk as the main binding site of anti-C1q antibodies Uwatoko et al. (1984, 1987)
1987 Anti-C1q associates with the occurrence of LN Wener et al. (1987); reviewed a. o. Trendelenburg (2005)
1991 C1q and anti-C1q are enriched in the glomeruli of LN Uwatoko et al. (1991)
1996 Identification of anti-C1q in mice Hogarth et al. (1996)
1993 Anti-C1q also present in healthy population and increase with age Siegert et al. (1993)
2004 Experimental evidence on how anti-C1q can be pathogenic to the kidney in LN but
not in healthy individuals
Trouw et al. (2004a)
2007 Identification of anti-C1q antibodies that target the globular heads Tsacheva et al. (2007)
Table 2 | Overview of commercially available assays for the detection of anti-C1q antibodies.
Trade name (P/N) Company Technology Reference
Anti-C1q autoantibody ELISA (EK-AC1QA) Buehlmann Laboratories AG ELISA Trendelenburg et al. (2006), Potlukova et al. (2008), Meyer
et al. (2009), Julkunen et al. (2012)
IMTEC-anti-C1q-antibodies (ITC59033) IMTEC ELISA Cai et al. (2010)
QUANTA lite anti-C1q (704565) INOVA Diagnostics ELISA Akhter et al. (2011)
Anti-C1q (ORG 549) Orgentec ELISA Heidenreich et al. (2009), Julkunen et al. (2012)
Anti-C1q (ORG 249) Orgentec Alegria NA
buffer (Vanhecke et al., 2012). In contrast to the assays reported
before that anti-C1q antibodies only target the collagen-like region
of C1q in 2007 it was discovered that there are also antibodies that
specifically target the globular head regions of C1q (Tsacheva et al.,
2007).
To study anti-C1q antibodies in experimental animal models,
assays were developed that used coating of purified mouse C1q and
high salt conditions similar to the human situation (Hogarth et al.,
1996; Trouw et al., 2003). Next, in order to circumvent the purifi-
cation of mouse C1q, an assay was developed which employed a
coating of C1q binding peptides, that captured C1q from Rag−/−
serum, as the antigenic entity for the anti-C1q ELISA (Trouw et al.,
2004a,b).
Several commercial assays are available for the detection of anti-
C1q antibodies (see Table 2). Those assays are mostly based on
the ELISA technology and are marketed by Bühlmann Laborato-
ries AG (CH-4124 Schönenbuch, Switzerland), IMTEC (HUMAN,
Wiesbaden, Germany), Orgentec (Mainz, Germany), and INOVA
Diagnostics (San Diego, CA, USA). The ALEGRIA system is a
semi-automated assay system based on patient specific modified
microtiter plate strips. Some of the anti-C1q antibody assays have
been used in clinical studies (Trendelenburg et al., 2006; Potlukova
and Kralikova, 2008; Heidenreich et al., 2009; Meyer et al., 2009;
Cai et al., 2010; Akhter et al., 2011; Julkunen et al., 2012). Until
today, none of the anti-C1q antibody assays achieved clearance
by the Food and Drug Administration (FDA) due to the lack
of prospective studies. In addition, systematic studies comparing
anti-C1q antibody assays from different companies are missing.
OCCURRENCE OF ANTI-C1Q AUTOANTIBODIES AND
CLINICAL ASSOCIATIONS
Over the past four decades anti-C1q autoantibodies have been
studied in a wide variety of autoimmune and renal conditions
as well as in infectious diseases (Trendelenburg, 2005). In the
healthy population the prevalence of anti-C1q autoantibodies
ranges between 2 and 8% (Wener et al., 1989; Siegert et al., 1992a;
Trendelenburg et al., 1999; Horvath et al., 2001a; Potlukova et al.,
2008) and increases with age (Siegert et al., 1993). Hypocom-
plementemic Urticarial Vasculitis Syndrome (HUVS) represents
the clinical condition with the highest percentage of anti-C1q
positivity; 100% (Wisnieski and Jones, 1992). Other conditions
characterized by high anti-C1q antibody prevalence are, mixed
connective tissue disease (94%), Felty’s syndrome (76%), and SLE
(30–60%) (Siegert et al., 1992a; Trendelenburg, 2005; Potlukova
et al., 2008; Sinico et al., 2009). The occurrence of anti-C1q autoan-
tibodies was shown to have familial clustering, indicating that there
is a genetic risk factor that together with environmental cues may
precipitate the production of these antibodies (Hunnangkul et al.,
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2008). Anti-C1q autoantibodies have also been described to occur
in infectious diseases although at a frequency of around, for exam-
ple 13% of HIV infected individuals vs. 5% in healthy controls
(Prohaszka et al., 1999) or up to 26% in patients suffering from
hepatitis C virus infection as compared to 10% of healthy controls
(Saadoun et al., 2006).
Especially the association between anti-C1q antibodies and
renal involvement in SLE has received much attention (Seelen et al.,
2003). Correct diagnosis of a flare of lupus nephritis (LN) still rep-
resents an important challenge. Serological identification of a flare
would be preferred over repeated renal biopsy. Although several
anti-nuclear antibodies are associated with renal involvement and
active disease (Heidenreich et al., 2009), the presence of anti-C1q
antibodies either alone or in combination with other serological
markers is superior to predict/correlate with active LN as reviewed
before (Trendelenburg, 2005; Sinico et al., 2009). Several stud-
ies provide evidence that anti-C1q autoantibodies are superior
to other serological markers in identifying a flare of LN (Mok
et al., 2010; Akhter et al., 2011). However, other studies indicate
that combinations of anti-C1q antibodies with other serological
markers are superior to anti-C1q antibodies alone (Matrat et al.,
2011; Julkunen et al., 2012; Yang et al., 2012). Especially strik-
ing is the strong negative predictive value of anti-C1q testing for
LN. In the absence of anti-C1q autoantibodies it is very unlikely
that a patient with LN will develop a flare (Trendelenburg et al.,
1999, 2006; Meyer et al., 2009; Mok et al., 2010; Matrat et al., 2011;
Moura et al., 2011). As many of these studies report on rather small
patient populations from very diverse ethnic backgrounds ranging
from Brazil (Moura et al., 2011), China (Zhang et al., 2011), India
(Pradhan et al., 2012), and Egypt (ElGendi and El-Sherif, 2009) it
is likely that considerable variation exists in the strength at which
anti-C1q antibodies are associated with and is predictive for LN
flares. Several of the larger studies from Europe and Hong Kong
point in the same direction (Moroni et al., 2001; Mok et al., 2010;
Julkunen et al., 2012) and also a recent meta-analysis confirmed
the diagnostic value of serum anti-C1q antibodies for LN (Yin
et al., 2012).
Whether or not anti-C1q antibodies are also associated with the
disease activity of LN remains to be established as currently there
is no consensus on this issue (Horvath et al., 2001b; Grootscholten
et al., 2007; Julkunen et al., 2012). One mechanism to clear anti-
C1q autoantibodies from the circulation is to use immunoabsorp-
tion on C1q-columns (Hiepe et al., 1999). This method depleted
next to circulating immune complexes also anti-C1q autoantibod-
ies and was shown to be beneficial in SLE patients (Berner et al.,
2001; Pfueller et al., 2001).
ANTI-C1Q ANTIBODIES AS PART OF MULTIPLEX
TECHNOLOGIES
With the emerging availability of multiplex technologies for the
detection of autoantibodies and other serological markers, the
combination of anti-C1q antibodies with other markers is facil-
itated (Papp et al., 2012). Recent studies have demonstrated that
biomarker profiles have the potential to improve the diagnosis of
SLE (Kalunian et al., 2012).
This is important also in the light of new treatment opportuni-
ties for SLE (Stohl and Hilbert, 2012) and personalized medicine
which seems to be just around the corner (Kalunian and Joan,
2009). The ultimate goal is to develop a panel of serological mark-
ers that are able to predict SLE flares which then can be prevented
by initiating the appropriate treatment. Especially life threatening
complications such as kidney failure and transplantation should
be prevented. Recently it has been described that anti-chromatin
(anti-nucleosome) antibodies are a promising serological marker
to help to predict the need for kidney transplantation (Stinton
et al., 2007). Whether testing for anti-C1q antibodies in a mul-
tiplex setting has the potential to contribute to the improved
management of LN patients remains a matter of further research.
PATHOGENIC CONSEQUENCES OF ANTI-C1Q
AUTOANTIBODIES
Several studies have addressed the mechanisms by which anti-
C1q autoantibodies may contribute to tissue damage, especially
in LN. Immune complexes eluted from affected glomeruli of
human patients and experimental animals revealed that there is
a strong enrichment of anti-C1q antibodies and that this deposi-
tion seemed to occur via solid-phase C1q (Uwatoko et al., 1991;
Mannik and Wener, 1997; Trouw et al., 2004b). Next to the pre-
viously mentioned clinical association studies also in vitro and
in vivo animal studies have been performed (Siegert et al., 1992b;
Hogarth et al., 1996; Trouw et al., 2004a,b; Bigler et al., 2011).
Several of the mouse models of lupus are characterized by a
progressive autoimmune disease in which autoantibodies are gen-
erated, immune complexes are formed followed by the occurrence
of severe glomerulonephritis. Depending on the mouse model
these autoimmune phenomena may evolve in different degrees of
severity and at different ages. Using MRL/lpr, BXSB, and NZB/W
mice, with a severe lupus phenotype, it was demonstrated that
anti-C1q autoantibodies are also present in mice and that an
increase in the titer of anti-C1q antibodies are associated with
the onset of nephritis (Hogarth et al., 1996; Trouw et al., 2004b).
Using a different model, using MRL/MpJ+/+ mice with a less
severe lupus phenotype, it was concluded that glomerulonephri-
tis may also occur in the absence of anti-C1q antibodies (Bigler
et al., 2011). In a more experimental setting, injection of rabbit
anti-mouse C1q antibodies resulted in immune-complex depo-
sition of C1q and anti-C1q antibodies but the limited degree of
deposition was insufficient to induce glomerulonephritis (Trouw
et al., 2003). However, injection of mouse anti-mouse C1q autoan-
tibodies into animals that have C1q containing immune com-
plexes in the glomeruli, resulted in strong glomerulonephritis
(Trouw et al., 2004a). Collectively these data indicate that anti-
C1q antibodies can be present in healthy subjects (mouse or
human) which might induce limited deposition in the kidney but
no nephritis. Only in the presence of C1q containing immune
complexes in the kidney, anti-C1q autoantibodies will amplify
the local complement activation and cellular influx resulting in
glomerulonephritis. A similar process may also be operational in
post-streptococcal glomerulonephritis where anti-C1q autoanti-
bodies were also found to associate with a worse disease course
(Kozyro et al., 2008). Why anti-C1q autoantibodies would pre-
dominantly enhance the tissue damage in glomeruli and not
or less pronounced in other tissues known to contain immune
complexes in lupus is currently unknown. The observation that
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anti-C1q autoantibodies may specifically target C1q bound to
early-apoptotic cells (Bigler et al., 2009) raises the question what
the in vivo consequences would be of enhanced complement acti-
vation on apoptotic cells. One possible scenario could be that the
natural mechanisms that would limit excessive complement acti-
vation on dying cells would be overruled (Trouw et al., 2007, 2008)
resulting in lysis of the cells and exposure of autoantigenic com-
ponents to the immune system. The observation that anti-C1q
autoantibodies are also observed in autoimmune thyroid diseases
and that their levels correlate with thyroid function (Potlukova
et al., 2008) may suggest that the effect of anti-C1q antibodies
amplifying immune-complex mediated damage only in the kid-
ney is incomplete and that the presence of anti-C1q antibodies
may enhance tissue damage in several other, unexpected clinical
conditions.
In conclusion; anti-C1q autoantibodies play an important role
in the clinical management of LN. Testing for anti-C1q autoanti-
bodies in large well defined cohorts of several diseases, preferable
in a prospective study design, is likely to provide additional clin-
ical conditions for which the testing for anti-C1q autoantibodies
would have clinical implications.
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